We describe a "fluorescence protection immunoassay," in which formation of an immune complex of a fluorescer-labeled antigen sterically protects the fluorescer from binding by antibodies to it. Competitive binding of unlabeled antigen by its antibody prevents formation of the fluorescer-labeled antigen immune complex, and allows anti-fluorescein to quench the fluorescence by binding to the fluorescer. This phenomenon is the basis of a new homogeneous assay technique that requires no separation step. The steric exclusion of anti-fluorescein from fluorescein-labeled human lgG immune complexes was altered by changing the molecular dimensions of both antifluorescein and the immune complex. The assay did not require highly purified fluorescein-labeled human IgG. An assay is demonstrated in which was used a fluoresceinlabeled human lgG conjugate containing lgG that was only 10% pure. Measurement of lgG in human serum samples correlated well with results by radial immunodiffusion. The method is applicable to the assay of both proteins and analytes of low molecular mass.
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In practice, several reagents usually must be combined, with or without an intervening incubation period. There are many homogeneous assay methods (1) (2) (3) (4) (5) (6) (7) (8) . Those in which fluorescent labels are used and which can be used to measure proteins and small molecules have limiting sensitivities near 10b0 mol of analyte per liter in the assay medium with presently available instrumentation (5) (6) (7) (8) (9) (10) (11) .
Previously described homogeneous fluorescence immunoassays (5) (6) (7) (8) (12, 13) , and the insensitivity of its fluorescence efficiency to nonspecific effects of serum. 
Materials and Methods

Steric Exclusion Principle
Evidence shown in Figure 3 suggests b Intensities were measured 10 mm after addition oftheanti-fluoresceinreagent and have been normalized to take into account temperature and concentration variations between runs.
fluorescence detector with a 20-tL flow cell, interfaced to a HP 9815A calculator.
Eight-nanometer bandpass filters were used that had an excitation peak transmission at 490 nm and emission peak transmission at 530 nm.
Results
Design of Fluorescence Protection Immunoassays
Human IgG and anti-human IgG were chosen for a model system because of ease of handling and stability of the immunoglobins.
Excess anti-fluorescein (anti-F) quenched the fluorescence of fluorescein-labeled human IgG by as much as 90% (Figure 2, curve A) A more satisfactory alternative was to measure the rate of fluorescence quenching rather than measuring the final fluorescence intensity. This "rate-fluorescence" method automatically subtracts the serum background fluorescence and obviates the need for a blank. Use of the "rate-fluorescence" protocol has the added advantage over the above described "end-point" assay that only one incubation is required.
After incubation of a mixture of the sample, fluorescein labeled antigen, and antibody, we added anti-fluorescein and immediately aspirated the mixture into the flow cell of a fluorometer.
The time course for quenching in an assay for human IgG is given in Figure 8 . Generally, rate measurements were made over a 30-to 60-s period after 10-s delay, to allow the temperature in the flow cell to equilibrate. Interestingly, for the rate measurements, it was found to be preferable to use anti-fluorescein Fab fragments because of their high rates of quenching, even though in end-point measurements Fab fragments produced less modulation of signal than does intact anti-fluorescein IgG.
Assays with Labeled Antigens of Low Purity
An important advantage of the fluorescence protection immunoassay method is its applicability to assays in which it is difficult to purify the protein used in preparing the labeled antigen. For example, in fluorescence excitation transfer immunoassays (6) fluorescer-labeled impurities in the antigen contribute directly to the background fluorescence because their signal cannot be modulated.
By contrast, in the fluorescence protection immunoassay, the fluorescer-labeled impurities are subject to quenching by anti-fluorescein. The amount of impurity that can be tolerated is limited by the extent to which the antifluorescer quenches the fluorescence. In the case of fluorescein, about 90% quenching was usually observed.
Thus a fluorescein-labeled protein mixture that To further reduce the effect of impurities, more efficient quenching of the fluorescein is required. This was achieved by labeling the anti-fluorescein with tetramethylrhodamine isothiocyanate.
The intrinsic quenching properties of the antibodies were thus augmented by dipole-coupled energy transfer from the bound fluorescein to the rhodamine ( Figure  9 ). The residual fluorescence was reduced from 10% with unlabeled antifluorescein to 2% with rhodamine-labeled antifluorescein.
A model system in which fluorescein labeled human IgG was deliberately adulterated with fluorescein labeled ovalbumin was studied, to simulate labeled impure protein and to determine the lowest degree of pure labeled IgG that the assay could tolerate.
A standard curve for a human IgG assay is given in Figure 10 , which shows an assay in which 10% pure labeled IgG and rhodamine labeled anti-fluorescein were used. An adequate assay range was achieved if an "end-point" protocol was used, and an assay could even be demonstrated with 5% pure labeled IgG. However, when we used the "rate fluorescence" protocol the labeled antigen had to be at least 20% pure, presumably because the rates of quenching the fluorescent impurities and fluorescent antigen were not sufficiently different. Theoretically, steric exclusion of antibody can affect not only the rate of binding of the antibody and antigen but also the effective binding affinity. The apparent approach to equilibrium with very large anti-fluorescers suggests that both effects may be important.
Discussion
However, the relative insensitivity of quenching to the binding affinity of the anti-fluorescein suggests that the rate of binding plays a predominant role.
It is of interest that when the assays were carried out according to the "rate fluorescence" protocol, the largest signal modulation was obtained using anti-fluorescein Fab fragments, the reagent that gave the least modulation in the "end-point" mode ( Figure 3 ). This apparent inconsistency results from the experimental design, which requires that the rates be measured over a fixed time interval (10- However, Figure 5 clearly illustrates that modulation of quenching by anti-fluorescein is independent of matrix formation.
Accordingly, the failure to even partly block binding by anti-fluorescein under these conditions must be related to a much higher rate of binding by anti-fluorescein than by anti-human IgG. Binding to a complex protein antigenic site will probably be slower than to a simple, symmetrical hapten because of a more negative entropy of activation; and antibody binding to proteins often requires a prior or concerted slow conformational change of the antigen. The preferred fluorescence immunoassay protocol will usually be the "rate fluorescence" measurement.
The need for higher purity of labeled antigens (>20% purity) with this protocol is more than offset by the elimination of an incubation period and by the automatic subtraction of serum background. Although the use of Fab fragments of the anti-fluorescer is preferred, intact antibodies can also be used in the rate mode. Increasing the bulk of the immune complex with second antibodies may offer some increase in the sensitivity of the "rate fluorescence" method, but this requires a fourth additional step and thus is not desirable. 
